Nirsevimab

Class
Antiviral agents
Subclass
Anti-RSV monoclonal antibodies
Substance name
Nirsevimab, nirsevimab‑alip
Brand names
Beyfortus®
Common formulations
Solution for injection
Dosage and administration
Pediatric patients
Prevention of RSV infection • Lower respiratory tract disease, neonates and infants born during or entering their first RSV season
Weight < 5 kg
•
50 mg IM × 1 at birth if born during the RSV season, or before the start of the season if born outside the RSV season
Weight ≥ 5 kg
•
100 mg IM × 1 at birth if born during the RSV season, or before the start of the season if born outside the RSV season
Indications for use
Labeled indications
Children
•
Prevention of RSV infection (in patients ≤ 24 months) (lower respiratory tract disease, remaining at risk for severe RSV disease through the second RSV season)
•
Prevention of RSV infection (lower respiratory tract disease, neonates and infants born in patients undergoing or entering their first RSV season)
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource